intestine, as do oligosaccharides and some resistant starches Epidemiological, clinical, animal and laboratory studies (3). In the large bowel, symbiotic bacteria ferment these have all provided evidence for the protective effects of carbohydrates releasing butyrate, a short chain fatty acid, as a non-steroidal anti-inflammatory drugs (NSAIDs), such as by-product (4). At physiological concentrations, butyrate has aspirin, against colorectal cancer. The main established been shown to induce growth inhibition, differentiation and target for NSAID action is cyclooxygenase (COX) and the apoptosis in colorectal tumour cells in vitro (5-7). These inducible isoform, COX-2, is up-regulated in colorectal observations may, in part, explain the correlation between a cancer. Rat intestinal epithelial cells transfected with a high fibre diet and low incidence of colorectal cancer. In COX-2 expression vector have previously been found to be animal models, butyrate, administered orally as gastroresistant, resistant to butyrate-induced apoptosis. Butyrate, a byslow release pellets, was found to increase apoptosis in the product of dietary fibre fermentation, is known to induce colonic mucosa of rats, thus providing further evidence that it differentiation and apoptosis in colorectal tumour cells may be beneficial against the development of colon cancer in vitro. In recent years there has been considerable interest (8) . Butyrate enemas have been suggested to be useful in longin the possible role of dietary fibre/resistant starch in the term therapy to reduce the risk of colon cancer in patients prevention of colorectal cancer. In this study we investigated with ulcerative colitis (9, 10) . A recent study demonstrated that whether inhibition of COX-2 with a highly selective COXbutyrate is able to enhance the sensitivity of colon carcinoma 2 inhibitor (NS-398) would sensitize human colorectal cell lines to Fas-mediated apoptosis (11) , thus suggesting that carcinoma cells to the growth inhibitory effect of butyrate.
butyrate may be an effective adjuvant for chemotherapy and HT29 and S/KS colorectal carcinoma cell lines were treated immunotherapy in colorectal cancer. for 72 h with 2 mM butyrate and/or 10 µM NS-398.
Epidemiological, clinical, animal and laboratory studies have Addition of 10 µM NS-398 alone (to inhibit COX-2 activity) all provided evidence for the protective effects of NSAIDs, did not result in detectable growth inhibition in either of such as aspirin and sulindac, against colorectal cancer (12) . the cell lines. NS-398 enhanced sensitivity to the growth Although the precise mechanisms for the protective effects of inhibitory effect of butyrate in HT29 cells expressing COXNSAIDs are unknown, the ability of these drugs to induce cell 2 protein. In contrast, NS-398 did not sensitize S/KS cycle arrest and apoptosis has received much attention in cells lacking detectable COX-2 protein and function (as recent years (reviewed in ref. 13 ). The most recognized determined by prostaglandin E 2 production) to the growth target for NSAIDs is COX (cyclooxygenase or prostaglandin inhibitory effect of butyrate. In addition, we report that endoperoxide synthase) (reviewed in ref. 14) , which is the butyrate treatment of carcinoma (HT29) and adenoma key enzyme in the conversion of arachidonic acid (AA) to (PC/AA/C1) cells leads to up-regulation of COX-2 protein.
prostaglandins and other eicosanoids (15). COX-1 is the Thus NS-398 only appears to sensitize human colorectal constitutive isoform, expressed in many mammalian tissues, carcinoma cells expressing COX-2 protein to the growth whereas COX-2 expression is undetectable in most tissues inhibitory effect of butyrate. As COX-2 is up-regulated under physiological conditions. Cytokines, growth factors, in colorectal carcinogenesis, this could have important oncogenes, serum and tumour promoters have been found to implications for the selective inhibition of cells expressing induce COX-2 expression (16) (17) (18) (19) (20) . COX-1 expression remains COX-2 protein over those lacking COX-2 protein expresunaltered in colorectal cancer, whereas COX-2 mRNA levels sion and for dietary modification to be considered alongside are increased in~85% of human colorectal cancers and in a NSAIDs in the prevention, and possibly treatment, of subset of adenomas (21) . Other studies have shown an increase colorectal cancer.
in COX-2 protein levels in adenomas (22) and in carcinomas (22) (23) (24) . Increased prostaglandin E 2 (PGE 2 ) synthesis has also been associated with colorectal neoplasia (25) , while various Introduction prostaglandins (including PGE 2 ) have been found to be growth In industrialized nations, colorectal cancer is a major cause of stimulatory to colon tumour cells in vitro (26) . COX-2 is cancer death and there is increasing urgency to develop suggested to play a key role in driving intestinal tumourigenesis. In vivo support for this comes from Oshima et al. (27) , effects of the agents, in some experiments the cells were treated for 7 days.
COX-2 selective inhibitors, such as NS-398 (28), are being fibre in the prevention of colorectal cancer, the aim of our Cells were stained for 10 min with 5 µg/ml acridine orange in phosphatebuffered saline (PBS) and were viewed immediately by fluorescence microstudy was to determine how human colorectal carcinoma cells colorectal carcinogenesis, would butyrate affect the regulation
SDS-PAGE western blotting
of COX-2 protein levels in cells? Answers to these questions Cells (1ϫ10 6 ) were washed in PBS and resuspended in 100 µl of gel sample may help us to design protocols for using dietary modification buffer (10% glycerol, 5% 2-mercaptoethanol, 4% SDS, 62.5 mM Tris-HCl, alongside COX-2 selective NSAIDs in the prevention of pH 6.75, 0.01% bromophenol blue). After incubation in a boiling water bath colorectal cancer.
for 5 min, samples were stored at -20°C. Proteins from cell lysate samples were resolved on 10 or 12.5% polyacrylamide gels and electroblotted onto Immobilon-P polyvinylidene difluoride membranes (Millipore, MA), which
Materials and methods
were probed with various primary antibodies. Polyclonal anti-COX-2 antibody Cell lines and culture conditions (a gift from Dr S.Prescott, University of Utah, Salt Lake City, UT) was used at a 1:400 dilution. This antibody is designed against the unique sequence in The colorectal carcinoma cell lines used in this study were HT29 and S/KS, the C-terminus of COX-2. Polyclonal anti-COX-1 antibody (Santa Cruz both of which have been described previously (5,31). PC/AA/C1 is a Biotechnology, CA) was used at a 1:400 dilution. Monoclonal anti-α-tubulin clonogenic, non-tumourigenic adenoma-derived cell line from a patient with (Sigma, UK) was used to control for loading and transfer at a 1:10 000 familial adenomatous polyposis (32,33). Cells were grown in T25 flasks dilution. The secondary antibodies were goat anti-rabbit (Sigma, UK), donkey (Corning Costar Europe) at 37°C in a 5% CO 2 incubator. For standard growth anti-goat (Santa Cruz Biotechnology, CA) and goat anti-mouse (Sigma, UK), conditions each cell line was grown in DMEM (Life Technologies, UK)
respectively. All were conjugated with horseradish peroxidase and used at a supplemented with 20% fetal bovine serum (batch selected), insulin (0.2 U/ 1:1000 dilution. Protein bands were visualized using an enhanced chemiluminml), glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 µg/ml).
escence detection system (Kirkegaard and Perry Laboratories, MD). EnzymThere was no addition of hydrocortisone sodium succinate to the medium, atically inactive native ovine COX-2 protein (Biogenesis Ltd, suppliers for due to its possible role in interfering with AA mobilization (the substrate for Oxford Biomedical Research, UK) was initially used as a positive control for COX) (34) .
COX-2 protein. This commercially available COX-2 protein positive control Cell treatments was compared with COX-2 protein expression in the HCA-7 cell line (37) (a A stock solution of 100 mM butyrate (Sigma, UK) was prepared in tissue gift from Dr S.Kirkland, Imperial College of Science, Technology and culture water (Life Technologies, UK) and diluted in standard growth medium Medicine, London, UK). This cell line is known to produce high levels of to give a final concentration of 1-6 mM butyrate. A stock solution of 30 mM COX-2 protein (38). After confirmation of the size of COX-2 protein, HCA-NS-398 (Cayman Chemical Co., MI) was prepared in dimethylsulphoxide 7 cells were also used as a COX-2 protein positive control. (DMSO) (AnalaR BDH, UK) and diluted in standard growth medium to give PGE 2 immunoassay a final concentration of 10-100 µM. Cell lines were seeded at a density of 1ϫ10 6 cells/T25 flask. Cultures at 70% confluence were incubated in butyrate-A Cayman Chemical Co. (MI) PGE 2 competitive enzyme immunoassay was used to measure PGE 2 levels in cell culture supernatants. Medium was supplemented medium, NS-398-supplemented medium or medium containing both agents for 3 days, unless otherwise stated. Control cultures received sampled, combined from replicate flasks and particulates removed by centrifugation. Aliquots of culture medium (1 ml) were stored at -70°C until assayed DMSO and tissue culture water, as appropriate. To determine the longer term undiluted. The immunoassay was carried out according to the manufacturer's protocol. The assay was sensitive to 30 pg PGE 2 /ml. PGE 2 production was normalized with respect to the number of adherent cells present in the particular culture at the time of sampling and the results are expressed as pg PGE 2 /10 6 cells. It was found that AA did not intrinsically affect the levels of PGE 2 detected for the standards in the assay.
Statistical analysis
For both cell lines separately, cell counts for control, butyrate alone, NS-398 alone and butyrate ϩ NS-398 were compared using analysis of variance (ANOVA) with a 5% significance level. The statistical model used included terms for experiment, treatment and the treatment by experiment interaction. In both cases, the interaction was not significant, meaning that the main effects could be interpreted. Further analysis was completed using contrasts for: (i) control versus NS-398 alone; (ii) the average of butyrate ϩ NS-398 together and butyrate alone versus control; (iii) butyrate ϩ NS-398 together versus butyrate alone. The level of significance was chosen as 5%.
Results

COX expression and PGE 2 production in human colorectal carcinoma cells
The colorectal carcinoma cell lines used in this study were HT29 and S/KS. Western blot analysis of cell lysates prepared from these cell lines confirmed constitutive expression of COX-2 protein in HT29 cells but there was no detectable COX-2 protein in S/KS cells ( Figure 1A ), which is in agreement with Elder et al. (39) . Two peptide bands of 72 and 74 kDa co-migrated with the COX-2 protein positive control and were identified as the COX-2 protein doublet. It is likely that these peptides represent different N-glycosylation states for the enzymatically active COX-2 molecules as described by Otto et al. (40) . COX-1 expression was detectable in both cell lines, with higher levels of expression in HT29 cells. PGE 2 production and its inhibition by the highly selective COX-2 inhibitor NS-398 for the HT29 cell line are shown in Figure 1B . able and this remained the case when S/KS cells were stimulated with up to 50 µM AA for 24 h (data not shown). This dose of AA did not affect attached cell yields for S/KS maximum concentration tested was 6 mM and the growth cells (data not shown). The lack of PGE 2 production in the inhibitory effect of butyrate increased up to this dose in a S/KS carcinoma cells, even after stimulation with AA, is dose-dependent manner. The effects of NS-398 were also consistent with the lack of detectable COX-2 protein in examined after 72 h. In agreement with previous studies (39), these cells. similar dose-dependent growth inhibition was seen in both cell
Butyrate and NS-398, a COX-2 selective NSAID, have doselines, with HT29 cells being slightly more sensitive (Figure dependent anti-proliferative effects in colorectal carcinoma 2B). NS-398 induces growth inhibition in S/KS cells despite cells
the lack of detectable COX-2 protein in these cells. A low dose of 10 µM NS-398 for 72 h resulted in attached cell yields Butyrate has previously been shown to induce growth inhibithat were similar to control values in both cell lines. Despite tion, differentiation and apoptosis in a variety of colorectal the lack of effect on growth of the cultures, this dose inhibited tumour cell lines (5-7). In this study, the effect of butyrate on COX-2 enzyme activity in HT29 cells ( Figure 1B) . Hence, a cell growth was determined after 72 h. Inhibition of growth dose of 10 µM NS-398 was chosen for the studies detailed of each cell line is indicated by the reduced attached cell yield of treated cultures versus control cultures (Figure 2A) . The below.
alone (26.4%, significant, P Ͻ 0.001) ( Figure 3A) . Treatment with both agents together also resulted in an increase in apoptosis compared with treatment with butyrate alone, as measured by the proportion of the cell population that was floating ( Figure 3B ). In contrast, when examining the attached cell yields for S/KS cells that have no detectable COX-2 protein, no difference was seen between butyrate treatment with NS-398 compared with butyrate treatment alone ( Figure  3C ). Similarly, there was no difference in the level of apoptosis seen for treatment of S/KS cells with butyrate alone and treatment with butyrate and NS-398 combined, as measured by the proportion of the cell population that was floating ( Figure 3D ). NS-398 was also able to sensitize HT29 cells, but not S/KS cells, to butyrate-induced growth inhibition and apoptosis after 7 days treatment, as well as after 3 days treatment. For example, for HT29 cells the decrease in attached cell yield compared with control values resulting from 7 days combined treatment with butyrate and NS-398 was 44.6% and greater than that seen for butyrate treatment alone (27.5%, significant, P Ͻ 0.001).
To confirm the induction of apoptosis, the morphological appearance of the floating cells was examined using fluorescence microscopy, following acridine orange staining of the cells. Previously, both butyrate and NS-398 have been shown to independently induce apoptosis in colorectal tumour cell lines (5,39). That the observed cell death was due to the induction of apoptosis was confirmed here, especially for combined treatment with butyrate and NS-398. The typically apoptotic appearance (condensed chromatin) of cells treated with both butyrate and NS-398 in the floating cell population of the HT29 cell line is illustrated in Figure 4 .
Butyrate up-regulates COX-2 protein levels
Due to the importance of COX-2 in colorectal cancer, we examined the cell lines used in the above studies for changes in COX protein expression, when treated with butyrate alone, The increase in COX-2 protein levels was reversible, indicating that the observed increase was not due to the selection of a NS-398 sensitizes colorectal carcinoma cells expressing COX-2 subpopulation of cells expressing elevated levels of COX-2 protein to the growth inhibitory effect of butyrate (data not shown). No change in COX-2 protein levels occurred with treatment with 10 µM NS-398 and this dose of NS-398 Tsujii and DuBois (30) found that permanently transfecting could not prevent the increase in COX-2 protein levels seen RIE cells with a COX-2 expression vector, resulting in elevated with butyrate treatment alone. COX-1 protein levels remained COX-2 protein, made these cells more resistant to butyrateconstant in both HT29 and S/KS cells upon treatment with induced apoptosis than the parental cell line. In this study we butyrate, NS-398 or both agents together. Having shown that asked whether, by using a highly selective COX-2 inhibitor butyrate increased COX-2 protein expression in colorectal (NS-398) to inhibit endogenous COX-2 enzyme activity, human carcinoma cells, we investigated whether the same effect colorectal carcinoma cells are made more sensitive to the occurred in a pre-malignant adenoma cell line. PC/AA/C1 growth inhibitory effect of butyrate. HT29 and S/KS cells adenoma cells, which constitutively express COX-2 protein, were treated with 2 mM butyrate (a dose that resulted in 25- were treated with 1-6 mM butyrate for 72 h. A dose-dependent 35% growth inhibition) with or without 10 µM NS-398 for 72 h.
increase in the amount of COX-2 protein was seen (Figure 6 ), In HT29 cells, with constitutive COX-2 protein expression, the which correlated with butyrate inducing growth inhibition and decrease in attached cell yield compared with control values apoptosis in this cell line (data not shown). As expected, for resulting from combining treatment with butyrate and NS-398 was 36.8% and greater than that seen for butyrate treatment HT29 carcinoma cells and PC/AA/C1 adenoma cells, the increase in COX-2 protein expression was found to correlate with an increase in PGE 2 secretion into the culture medium. For example, for the HT29 carcinoma cells, PGE 2 secretion increased 24-fold, from 37 pg PGE 2 /10 6 cells for control treatment to 910 pg PGE 2 /10 6 cells for 4 mM butyrate treatment after 72 h. For the PC/AA/C1 adenoma cells, PGE 2 secretion increased 9-fold, from Ͻ8 pg PGE 2 /10 6 cells for control treatment to 75 pg PGE 2 /10 6 cells for 4 mM butyrate treatment after 72 h.
Discussion
In this study we investigated whether treatment of colorectal carcinoma cell lines with a COX-2 selective NSAID could enhance the growth inhibitory effect of butyrate. Interest stemmed from the fact that there is evidence that a high fibre diet and the use of NSAIDs are preventive for colorectal cancer. The ability of butyrate (a short chain fatty acid released by the fermentation of dietary fibre in the large bowel) and NSAIDs to independently induce growth inhibition and apoptosis in colorectal tumour cell lines may, in part, explain their protective role in vivo. We have shown differences in the the COX-2 protein status of the cells. NS-398 was used at a dose which was not growth inhibitory to the cells but which salicylate did not sensitize the cells to butyrate-induced growth inhibition, this may reflect the relatively poor COX-inhibitory inhibited COX-2 enzyme activity in COX-2 positive cells. In colorectal carcinoma cells expressing COX-2 protein, NS-398 properties of salicylate. Kamitani et al. (42) found that combining indomethacin (an NSAID selective for COX-1 over COXsensitized the cells to the growth inhibitory effect of butyrate, whereas in colorectal carcinoma cells lacking detectable COX-2) with butyrate made no difference to the levels of apoptosis induced by butyrate treatment alone in Caco-2 cells that 2 protein and function (as determined by PGE 2 production), NS-398 did not sensitize cells to the effect of butyrate. We express COX-2 protein. Hence, the effects on butyrate-induced growth inhibition and apoptosis are highly dependent on the have recently examined another colorectal carcinoma cell line expressing COX-2 protein (HCA-7) for sensitization by colorectal tumour cell line examined and whether 'traditional' NSAIDs are used compared with COX-2 selective NSAIDs. NS-398 to butyrate-induced growth inhibition. NS-398 was also found to enhance the growth inhibitory effect of butyrate Although NSAIDs are known to have effects on a large number of parameters, including cell proliferation, apoptosis, in these cells (T.E.Crew, D.J.E.Elder and C.Paraskeva, unpublished results). As with HT29 cells, NS-398 was shown to immune surveillance and angiogenesis (12) , apoptosis is considered to be their main anti-proliferative effect in vitro and decrease the level of PGE 2 in the culture medium of HCA-7 cells. Although we have found that NS-398 sensitizes HT29 in vivo (13) . In the current study comparing the HT29 (COX-2 positive) and S/KS (COX-2 negative) colorectal carcinoma carcinoma cells to the growth inhibitory effect of butyrate, salicylate (the active metabolite of aspirin) and butyrate were cell lines, as well as examining growth inhibitory effects, we asked whether NS-398 was able to sensitize the cells to only found to have additive (but not greater than additive) growth inhibitory effects upon treatment of HT29 cells butyrate-induced apoptosis. NS-398 was seen to enhance butyrate-induced apoptosis in HT29 cells but not in S/KS cells. (D.J.E.Elder and C.Paraskeva, unpublished results). As These data imply that both growth inhibition and apoptosis the increase in COX-2 protein by butyrate suggests that the increase in COX-2 protein is independent of prostaglandin may be important responses of the cells to the combined treatment with butyrate and NS-398. Even though the difference synthesis. These data may go some way to explain previous studies between the level of apoptosis induced by butyrate treatment alone compared with the level induced by butyrate treatment which have reported that agents such as NSAIDs and TGFβ, at doses causing growth inhibition and apoptosis, can cause with NS-398 is small in HT29 cells, low levels of apoptosis (if not balanced by proliferation) can result in significant tissue an increase in COX-2 protein expression (49-52). In our hands, TGFβ treatment of an adenoma cell line that responds regression over time (43) . Hence, with prolonged treatment in vivo with a COX-2 selective NSAID and a high fibre/ by growth inhibition and cell death by apoptosis results in an increase in COX-2 protein (T.E.Crew, A.Hague,D.J.E.Elder resistant starch diet (resulting in a high level of lumenal butyrate), minor differences in the sensitivity of cells to and C.Paraskeva, unpublished results). This is in agreement with Sheng et al. (52) , where chronic TGFβ treatment of rat undergo apoptosis may result in the relative regression of COX-2-positive tumour tissue.
intestinal epithelial cells up-regulated COX-2 protein levels and increased the tumourigenic potential of the cells. Other Given that the majority of colorectal tumours have increased COX-2 protein (23, 24) , an effective high fibre diet may enable 'stresses', such as ceramide, UV light and deoxycholate, have also been found to lead to an up-regulation of COX-2 protein lower doses of COX-2 selective NSAIDs to be used in the prevention of colorectal cancer. This may further reduce the (48, 53, 54) . In contrast to the data reported in our study, it has previously been reported that butyrate down-regulates potential side-effects from using such drugs and thus dietary modification during drug treatment may be one way of increasexpression of COX-2 protein in Caco-2 cells, under conditions where butyrate induces apoptosis in these cells (42). ing the efficacy of chemopreventive agents.
Other studies have combined two agents to investigate In summary, we report here for the first time that butyrate treatment of adenoma and carcinoma cells leads to the upwhether one agent can sensitize cells to the actions of another agent. For example, in human fibroblasts butyrate has been regulation of COX-2 protein (in association with growth inhibition and apoptosis). Furthermore, we have shown that found to act in synergy with ionizing radiation, UV light and cisplatin to induce apoptosis, perhaps by lowering the level of NS-398 is able to sensitize HT29 cells (COX-2 positive) to the growth inhibitory effect of butyrate but is unable to BclX L (an apoptosis antagonist) in cells (44). Suganuma et al. (45) found that drinking green tea could potentially enhance sensitize S/KS cells (COX-2 negative) to butyrate-induced growth inhibition. For the majority of colorectal tumours that the cancer preventive activity of sulindac (a 'traditional' NSAID) and Bonnotte et al. (11) showed dramatic enhancement express COX-2, this may mean that a high fibre/resistant starch diet could enable lower doses of COX-2 selective NSAIDs to of the sensitivity of colon carcinoma cell lines to Fas-mediated apoptosis after treatment with butyrate. The clinical toxicity be used in chemoprevention. We are a long way from fully understanding the regulation of the COX-2 gene but it continues of butyrate is low and the authors of the latter paper propose that butyrate may be a useful adjuvant in therapeutic trials. In to be an established area of research, which will hopefully lead to a greater understanding of colorectal cancer in terms many studies, butyrate has been the agent that sensitizes cells to the effects of another agent, whereas our study is the first of the molecular pathways involved and provide potential applications for the clinic. known report of a COX-2 selective inhibitor being able to sensitize colorectal carcinoma cells expressing COX-2 protein to butyrate-induced growth inhibition. Hence, the question
